Susquehanna Portfolio Strategies’s Blueprint Medicines BPMC Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-135,057	Closed	-$17.3M	–	1037
2025 Q2	$17.3M	Buy	+135,057	New	+$14M	0.38%	63
2024 Q3	–	Sell	-40,277	Closed	-$4.34M	–	369
2024 Q2	$4.34M	Sell	40,277 -57,540	-59%	-$5.76M	0.18%	135
2024 Q1	$9.28M	Hold	97,817	–	–	0.22%	135
2023 Q4	$9.02M	Buy	+97,817	New	+$6.34M	0.16%	187

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna Portfolio Strategies's BPMC Position: Q3 2025 in Review

Susquehanna Portfolio Strategies sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 135,057 shares — an estimated $17.3M sold.

Susquehanna Portfolio Strategies first reported a position in BPMC in Q4 2023 and held it in 4 quarters. The position peaked at $17.3M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Susquehanna Portfolio Strategies reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Susquehanna Portfolio Strategies sold 135,057 Blueprint Medicines shares in Q3 2025, an estimated $17.3M.
Susquehanna Portfolio Strategies first reported a position in Blueprint Medicines in Q4 2023 and held it in 4 quarters.
Susquehanna Portfolio Strategies's Blueprint Medicines position peaked at $17.3M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Susquehanna Portfolio Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.